Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Andersson Y, Løvstakken E, Herud TM, Waagene S, Flatmark K, Fleten KG (2025)
Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian Cancer
Ann Surg Oncol (in press)
DOI 10.1245/s10434-025-18025-x, PubMed 40788597

Apostol AI, Kotsopoulos J, Gronwald J, Kim RH, Karlan BY, Aeilts A, Cajal TRY, Pal T, Eisen A, Bordeleau L, Foulkes WD, Couch F, Zakalik D, Fruscio R, Sun P, Lubinski J, Tung N, Singer CF, Moller P, Dominguez-Valentin M, Narod SA, Metcalfe K, Hereditary Breast Cancer Clinical Study Group (2025)
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant
Gynecol Oncol, 201, 44-52 (in press)
DOI 10.1016/j.ygyno.2025.07.030, PubMed 40784323